So far, the only FDA approved agents for treatment of metastatic melanoma are cytostatic DTIC and immunotherapeutic Interleukin-2 (IL-2), ipilimumab, an anti-CTLA4-antibody and nivolumab, which blocks the programmed cell death protein 1 (PD-1) of T-cells. This evidence concerns the gene IL2 and metastatic melanoma.